3SBio Inc. is a biotechnology company. The Company is focused on researching, developing, manufacturing and marketing biopharmaceutical products. The Company primarily focuses on product candidates in two core therapeutic areas, such as nephrology and oncology. The Company has three research and development platforms, including a mammalian cell-based platform, a bacterial cell-based platform and a chemical platform. Its core products include TPIAO and EPIAO. The Company's TPIAO is a commercialized recombinant human thrombopoietin (rhTPO) product used for the treatment of certain types of thrombocytopenia, a deficiency of platelets. The Company's EPIAO is an injectable recombinant human erythropoietin (rhEPO). The Company's other products include IV Iron Sucrose, Inleusin, Intefen, SEPO, Sparin, Metadoxine, Docetaxel, Anastrozole, Azasetron, Amikacin and Qiming Keli. The Company maintains operation facilities in Shenyang, Benxi, Hangzhou and Shenzhen, as well as in Como, Italy.